Additional results from clinical phase 1 study
SpectraCure is conducting a Phase 1 clinical trial for the treatment of patients with relapse of prostate cancer, using the company's photodynamic therapy (PDT) technology. As previously announced, the fourth patient was treated on February 22nd at the Princess Margaret Cancer Centre in Toronto. During the follow-up after treatment, patients' PSA values are monitored on […]
Communiqué from the Annual General Meeting 2017
At the SpectraCures AGM held in Lund on 23 May 2017, the following decisions were taken. Decisions concerning the adoption of the income statement and balance sheet, etc. The AGM resolved to adopt the income statement and balance sheet for the financial year 2016. The Board of Directors and the Managing director were granted discharge […]
Notice of annual general Meeting of SpectraCure AB (publ)
The shareholders of SpectraCure AB (publ), Org.nr 556642-1011 ("the Company") are hereby invited to the annual general meeting on Tuesday 23 May 2017 at. 11.00 at the company's premises, Magistratsvägen 10, 226 43 Lund. Notifications, etc., Shareholders who wish to participate in the annual general meeting must: be entered in the share register maintained by […]
